Literature DB >> 6713419

Differences in lipid composition of doxorubicin-sensitive and -resistant P388 cells.

A Ramu, D Glaubiger, H Weintraub.   

Abstract

An anthracycline-resistant subline of P388 murine leukemia cells, P388/ADR, has been shown to have an altered total lipid content and composition when compared to the parent line. When specific lipids of the cell lines are compared, it is found that P388/ADR cells contain approximately 3.6 times the amount of triglycerides as P388 cells. Although no differences are noted in the amounts of unesterified cholesterol or total phospholipids in the two cell lines, they do differ in specific phospholipid patterns. P388/ADR cells contain relatively less phosphatidylcholine and more sphingomyelin than drug-sensitive cells. No differences are observed in the content of phosphatidylethanolamine and cardiolipin. The difference in phosphatidylcholine/sphingomyelin ratio (5.57 for ADR-sensitive cells and 3.28 for ADR-resistant cells) may account for the previously observed difference in plasma membrane lipid structural order between these cell lines. Measurements of the relative activity of phosphocholine transferase in the two lines, using the rate of incorporation of 3H-choline into phosphatidylcholine, indicate that lower phosphocholine transferase activity in P388/ADR cells may account for the observed changes in cellular lipid and phospholipid composition.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6713419

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  16 in total

Review 1.  Changes in lipid and protein constituents of rafts and caveolae in multidrug resistant cancer cells and their functional consequences.

Authors:  Y Lavie; M Liscovitch
Journal:  Glycoconj J       Date:  2000 Mar-Apr       Impact factor: 2.916

2.  Expressions of resistance and cross-resistance in teniposide-resistant L1210 cells.

Authors:  D Roberts; T Lee; E Parganas; L Wiggins; J Yalowich; R Ashmun
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  Sustained Epigenetic Drug Delivery Depletes Cholesterol-Sphingomyelin Rafts from Resistant Breast Cancer Cells, Influencing Biophysical Characteristics of Membrane Lipids.

Authors:  Vijay Raghavan; Sivakumar Vijayaraghavalu; Chiranjeevi Peetla; Masayoshi Yamada; Megan Morisada; Vinod Labhasetwar
Journal:  Langmuir       Date:  2015-10-15       Impact factor: 3.882

Review 4.  Biophysics of cell membrane lipids in cancer drug resistance: Implications for drug transport and drug delivery with nanoparticles.

Authors:  Chiranjeevi Peetla; Sivakumar Vijayaraghavalu; Vinod Labhasetwar
Journal:  Adv Drug Deliv Rev       Date:  2013-09-19       Impact factor: 15.470

Review 5.  Sphingolipid abnormalities in cancer multidrug resistance: Chicken or egg?

Authors:  Wing-Kee Lee; Richard N Kolesnick
Journal:  Cell Signal       Date:  2017-07-04       Impact factor: 4.315

6.  Inhibition of glycosphingolipid biosynthesis reverts multidrug resistance by differentially modulating ABC transporters in chronic myeloid leukemias.

Authors:  Eduardo J Salustiano; Kelli M da Costa; Leonardo Freire-de-Lima; Lucia Mendonça-Previato; José O Previato
Journal:  J Biol Chem       Date:  2020-03-30       Impact factor: 5.157

7.  Modulation of induced resistance to adriamycin in two human breast cancer cell lines with tamoxifen or perhexiline maleate.

Authors:  B J Foster; K R Grotzinger; W M McKoy; L V Rubinstein; T C Hamilton
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

8.  Characterization of cellular lipids in doxorubicin-sensitive and -resistant P388 mouse leukemia cells.

Authors:  W M Holleran; M W DeGregorio; R Ganapathi; J R Wilbur; B A Macher
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

9.  Lipoproteins in hypoxic tumor cells as traps of free radicals.

Authors:  P M Schwartsburd; V Z Lankin
Journal:  Med Oncol       Date:  1994       Impact factor: 3.064

10.  Membrane fatty acid modification in tumor cells: a potential therapeutic adjunct.

Authors:  C P Burns; A A Spector
Journal:  Lipids       Date:  1987-03       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.